Krishna Institute of Medical Sciences Ltd filed its audited standalone and consolidated financial statements for the financial year ended March 31, 2026. The filing confirms that the company maintained adequate internal financial controls over financial reporting during the period. The results, approved by the Board of Directors on May 15, 2026, are subject to adoption by shareholders at the ensuing Annual General Meeting.

The Statutory Auditors, S.R. Batliboi & Associates LLP, issued an audit report dated May 15, 2026. The report confirms that the company used accounting software with an audit trail feature that operated throughout the year for all relevant transactions. The auditors stated they did not encounter any instance of the audit trail feature being tampered with during the course of the audit.

Regarding the consolidated financial statements, the auditors reported that the group and its associate companies, incorporated in India, maintained adequate internal financial controls. These controls were operating effectively as at March 31, 2026, based on criteria established by the company considering the essential components of internal control stated in the Guidance Note issued by the ICAI.

The auditors also addressed other legal and regulatory requirements in their report. They confirmed that the company did not incur cash losses in the current financial year or in the immediately preceding financial year. Furthermore, there was no resignation of the statutory auditors during the year.

The company stated that no dividend was declared or paid during the year by the holding company, its subsidiaries, or the associate company incorporated in India. The audit trail of prior years has been preserved by the company as per statutory requirements for record retention to the extent it was enabled and recorded in the respective year.

Krishna Institute of Medical Sciences Limited has approved the preferential allotment of 77,02,182 warrants to members of its promoter and promoter group, aggregating to ₹599,99,99,778. The Board of Directors approved the proposal on June 13, 2026, issuing warrants fully convertible into equity shares with a face value of ₹2 each at a price of ₹779, including a premium of ₹777. The allotment is subject to shareholder and regulatory approvals, with an Extra-Ordinary General Meeting (EGM) scheduled for July 9, 2026, to seek consent.

The warrants will be issued to Dr. Abhinay Bollineni, Mr. Adwik Bollineni, and Bharas Ventures LLP. Dr. Abhinay Bollineni and Mr. Adwik Bollineni will receive 32,09,242 warrants each, while Bharas Ventures LLP will receive 12,83,698 warrants. The issue price is determined in accordance with Regulation 164 of the SEBI ICDR Regulations and the company's articles of association, based on a valuation report from a registered valuer. The relevant date for determining the issue price is June 9, 2026.

Details of the Preferential Allotment

The following table outlines the allotment details for each allottee under the preferential warrant issuance:

Warrant Terms and Conditions

The warrants are exercisable in one or more tranches within 18 months from the date of allotment. An amount equivalent to 25% of the warrant issue price is payable at the time of subscription, with the balance 75% due upon conversion. If the warrants are not exercised within the 18-month period, the entitlement will lapse, and any amount paid will be forfeited.

The Board also approved the draft notice for the EGM, which will be conducted via video conferencing. The company stated that the fund raising aims to bolster its capital base. The trading window for designated persons and their immediate relatives remains closed until 48 hours after the board meeting's conclusion.